tcsc0598 Bardoxolone (methyl)

Bardoxolone is a synthetic triterpenoid compound with potential antineoplastic and anti-inflammatory activities, acting as an activator of the Nrf2 pathway and an inhibitor of the NF-κB pathway.

IC50 & Target: Nrf2^[1]

In Vivo: Bardoxolone Methyl (30 mg/kg, p.o.) decreases renal expression of megalin but not cubilin, increases creatinine clearance and urinary albumin-to-creatinine ratios, and induces Nrf2 cytoprotective targets in cynomolgus monkeys^[1]. Bardoxolone Methyl could induce overall favorable effects on the heart via its improvement in eGFR in both animal models and clinical trials^[2].